Piper Sandler analyst Kelsey Goodwin initiated coverage of Janux Therapeutics (JANX) with an Overweight rating and $42 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Buy Rating for Janux Therapeutics Driven by Promising Tumor-Conditional Masking Platform and Strategic Collaborations
- Promising Future for Janux Therapeutics: Buy Rating Backed by Strong Clinical Profile and Strategic Trials
- Promising Developments and Strategic Expansion at Janux Therapeutics: Analyst Sets $70 Price Target
- Buy Rating for Janux Therapeutics Driven by Promising Pipeline and Strong Financial Position
- Janux Therapeutics Reports Q2 2025 Financial Results